文献速递前列腺癌

使用前列腺特异性膜抗原正电子发射断层显像引导前列腺穿刺活检并对高危前列腺癌男性进行分期

Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
PubMed 文献 · BJU Int · 2023-09-13

这项前瞻性非随机队列研究纳入60例PSA 20-50 ng/mL的活检初治高危男性,未行MRI,直接以18F-PSMA(DCFPyL)-PET/CT作为单一影像引导靶向穿刺联合系统穿刺。联合穿刺检出前列腺癌56/60(93.3%),其中52例(92.9%)为临床显著前列腺癌;靶向穿刺单用检出52/60(86.7%),在27例转移患者中全部检出。

要点

  • PSMA-PET/CT作为单一影像引导穿刺,联合系统穿刺检出临床显著前列腺癌比例高。
  • 27/60(45%)患者在分期PSMA-PET/CT上已存在转移性疾病。
  • 靶向穿刺单用在27例转移患者中全部检出前列腺癌,联合穿刺检出率更高。

核心结论

  • 在活检初治高危前列腺癌男性中采用PSMA驱动的单一影像通路,可避免大量诊断性MRI扫描,同时获得充分的靶向、分期和临床显著前列腺癌检出。

研究设计与样本

  • 前瞻性非随机队列研究,纳入60例PSA水平20-50 ng/mL的活检初治高危男性患者,未行MRI。

主要发现

  • 所有PSMA-PET/CT均在前列腺内观察到可疑前列腺癌病灶。
  • 27/60(45%)患者在分期18F-PSMA(DCFPyL)-PET/CT上已存在转移性疾病。
  • 联合PSMA引导靶向穿刺与系统穿刺检出前列腺癌56/60(93.3%),其中52例(92.9%)为临床显著前列腺癌。
  • PSMA引导靶向穿刺若作为单一穿刺方式,检出前列腺癌52/60(86.7%),在27/27(100%)转移患者中检出。

关键数值与推荐

  • 临床显著前列腺癌定义为前列腺穿刺国际泌尿病理学会(ISUP)分级分组≥2。
  • 采用前列腺12段映射模型进行PSMA引导靶向穿刺联合系统穿刺。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether a diagnostic pathway in which prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) is used as a single imaging modality is feasible to guide targeted biopsy and to detect clinically significant prostate cancer (csPCa) in biopsy-naïve men at high-risk of disease. PATIENTS AND METHODS: A total of 60 men with a prostate-specific antigen (PSA) level of 20-50 ng/mL underwent 18 F-PSMA(DCFPyL)-PET/CT prior to prostate biopsies in this prospective, non-randomised cohort study. Magnetic resonance imaging (MRI) was not performed. Using a 12-segment mapping model of the prostate, PSMA-guided targeted biopsy was performed along with systematic biopsies. The detection rate of PCa and csPCa was assessed for combined systematic and targeted biopsy, and for targeted biopsy only. csPCa was defined as a prostate biopsy with an International Society of Uropathology (ISUP) Grade Group ≥2. RESULTS: Lesions suspicious for PCa in the prostate gland were observed on all PSMA-PET/CTs. A total of 27/60 men (45%) already had metastatic disease on staging 18 F-PSMA(DCFPyL)-PET/CT. Combined PSMA-guided targeted and systematic biopsies detected PCa in 56/60 (93.3%) patients, with 52 of them (92.9%) having csPCa. PSMA-guided targeted biopsy, if performed as a single biopsy modality, identified PCa in 52/60 men (86.7%) and in 27/27 men (100%) men with metastases. CONCLUSIONS: Using the PSMA-driven single imaging modality pathway in biopsy-naïve men at high-risk of PCa, a substantial number of diagnostic MRI scans could be avoided while at the same time obtaining adequate targeting, staging, and detection of csPCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bodar YJL, Boevé LMS, van Leeuwen PJ, et al. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer. BJU Int. 2023. PMID: 37620288. doi:10.1111/bju.16167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。